blind, placebo-controlled trial

1 Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine Home Journals Specialties The Lancet Clinic Global Health Multimedia Campaigns More Information for Submit a Paper Login | Register | Claim Your Subscription | Subscribe Online First Current Issue All Issues Multimedia About the Journal Advisory Board AllContent All Content Search Search Advanced Search < Previous Article Volume 6, No. 2, p97 106, February 2018 Next Article > Access this article on ScienceDirect Articles Article Options Oral prednisolone in preschool children with virus- PDF (680 KB). associated wheeze: a prospective, randomised, double- Download Images(.ppt). blind, placebo-controlled trial Email Article S J Foster, MBBS, M N Cooper, BSc, S Oosterhof, MBBS, M L Borland, MBBS.

2 Add to My Reading List Published: 15 January 2018. Export Citation PlumX Metrics Create Citation Alert Cited by in Scopus (1). Request Permissions Mentions Order Reprints News Mentions: 1. Social Media (100 minimum order). Tweets: 138. Citations Citation Indexes: 1. see details Linked Articles DOI: (18)30008-0 |. (18)30008-0/fulltext[2018/03/04 23:07:55]. Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine COMMENT. Article Info Oral corticosteroids reduce length of hospital stay for preschool children Summary Full Text Tables and Figures References Supplementary Material with virus-associated wheeze Summary CORRECTIONS. Background Corrections Children of preschool age often have episodes of virus-associated wheeze, and research assessing efficacy of corticosteroids for paediatric wheeze exacerbations is inconclusive.

3 Methods This non-inferiority, randomised, double-blind, placebo-controlled trial was to compare the efficacy of placebo versus oral prednisolone in children aged 24 72 months presenting with virus-associated wheeze at the paediatric emergency department of Princess Margaret Hospital in Perth, WA, Australia. Eligible participants were randomly assigned (1:1) using a computer-generated random number program to receive placebo or prednisolone (1 mg/kg per Related Clinics day) for 3 days. The primary outcome was total length of stay in hospital until ready for discharge. Following an analysis to test the hypothesis that placebo is non-inferior to 1 2. prednisolone, a post-hoc superiority analysis was done to test the hypothesis that prednisolone was superior to placebo.

4 A non-inferiority margin of 10% was used to establish Asthma non-inferiority. Efficacy analyses were on a modified intention-to-treat basis, whereby patients were excluded from the final efficacy analysis if consent was withdrawn, two doses of study drug were vomited, or paperwork was lost. All participants were included in safety analyses. Popular Articles This study is registered with the Australian and New Zealand Clinical Trials Registry, number ACTRN12612000394842. Most Read Most Cited Findings Most read in The Lancet Respiratory Between June 11, 2012, and June 10, 2015, we screened 3727 patients for eligibility. 624 Medicine within the past 30 days. eligible patients were randomly assigned to treatment, and 605 patients were included in the modified intention-to-treat analysis (300 patients from the placebo group, 305 patients from the prednisolone group).

5 The median length of stay until ready for discharge was longer in the placebo group (540 min [IQR 124 971]) than in the prednisolone group (370 min [121 709]); ARTICLES. Global, regional, and national placebo was inferior to prednisolone. In the post-hoc superiority analysis of 605 patients, the deaths, prevalence, disability- unadjusted ratio of geometric mean for length of stay was 0 79 (95% CI 0 64 0 97; p=0 0227) adjusted life years, and years lived for the prednisolone group relative to the placebo group. No serious adverse events were with disability for chronic reported during the study or follow-up period. One child in the placebo group had a non- obstructive pulmonary disease and asthma, 1990 2015: a systematic specific maculopapular rash, which resolved spontaneously.

6 Two children (one from each analysis for the Global Burden of group) were reported to be hyperactive during follow-up assessments. Disease Study 2015. Vol. 5, No. 9. Interpretation Published: August 16, 2017. Oral prednisolone had a clear benefit over placebo at reducing the length of stay in children Open Access presenting to a paediatric emergency department with virus-associated wheeze and was well tolerated. ARTICLES. Physiotherapy breathing retraining for asthma: a randomised controlled Funding trial Western Australian Department of Health. Vol. 6, No. 1. Published: December 13, 2017. Open Access To read this article in full you will need to make a payment REVIEW. Already registered? Please login. Payment Options Diagnostic criteria for idiopathic Purchase this article for $ pulmonary fibrosis: a Fleischner Login to existing account Society White Paper USD.

7 Online access for 24 hours Vol. 6, No. 2. PDF version can be downloaded Published: November 15, 2017. Forgot password? as your permanent record ARTICLES. Subscribe to The Lancet Effect of lung deflation with Respiratory Medicine indacaterol plus glycopyrronium on Purchase a subscription to gain ventricular filling in patients with access to this and all other articles in hyperinflation and COPD (CLAIM): a this journal. double-blind, randomised, Register crossover, placebo-controlled , Create a new account Options include: single-centre trial (18)30008-0/fulltext[2018/03/04 23:07:55]. Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine Personal online only subscription Published: February 21, 2018.

8 The Lancet Choice Access any 5 articles from The Institutional Access CORRESPONDENCE. Lancet family of journals Visit ScienceDirect to see if you have Diagnostic criteria for idiopathic Full text and PDF access to 5. access via your institution. pulmonary fibrosis paywall articles of your choice Valid for 365 days from date of Vol. 6, No. 2. purchase Published: February, 2018. Find out more about The Lancet Already a print subscriber? Choice Claim online access Have a free trial code? Activate your free trial The Lancet Journals The Lancet The Lancet HIV. Information & Support Subscription The Lancet Child & Adolescent The Lancet Infectious Diseases Health The Lancet Neurology About Us Your Account The Lancet Diabetes & The Lancet Oncology Information for Authors Subscription Options Endocrinology The Lancet Planetary Health Information for Readers Existing Print Subscribers The Lancet Gastroenterology & The Lancet Psychiatry The Lancet Careers Hepatology The Lancet Public Health Customer Service The Lancet Global Health The Lancet Respiratory Medicine Contact Us The Lancet Haematology EBioMedicine Privacy Policy Terms and Conditions Copyright 2018 Elsevier Limited except certain content provided by third parties.

9 The Lancet is a trade mark of Elsevier Limited. The website is operated by Elsevier Inc. The content on this site is intended for health professionals. Cookies are set by this site. To decline them or learn more, visit our Cookies page. The Lancet demonstrates its commitment to accessibility by enabling access and optimising the experience for individuals with disabilities and impairments. (18)30008-0/fulltext[2018/03/04 23:07:55].